Efficacy of ravuconazole in a murine model of vaginitis by Candida albicans.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Revista Iberoamericana de Micologia

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.riam.2013.09.006PMID 24071640
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs.

  2012cited by this paper
• Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in Kenya

  2011cited by this paper
• Candida Infections of the Genitourinary Tract

  2010cited by this paper
• Therapeutic efficacy of voriconazole against a fluconazole-resistant Candida albicans isolate in a vaginal model.

  2009cited by this paper
• Efficacy of Albaconazole against Candida albicans in a Vaginitis Model

  2009cited by this paper
• Therapeutic efficacy of posaconazole against isolates of Candida albicans with different susceptibilities to fluconazole in a vaginal model.

  2007cited by this paper
• International Surveillance of Candida spp. and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2003)

  2006cited by this paper
• In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi.

  2005cited by this paper
• In Vitro Activities of Ravuconazole and Four Other Antifungal Agents against Fluconazole-Resistant or -Susceptible Clinical Yeast Isolates

  2004cited by this paper
• Efficacy, Safety, and Plasma Pharmacokinetics of Escalating Dosages of Intravenously Administered Ravuconazole Lysine Phosphoester for Treatment of Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits

  2004cited by this paper
• In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents.

  2004cited by this paper
• Activities of Caspofungin, Itraconazole, Posaconazole, Ravuconazole, Voriconazole, and Amphotericin B against 448 Recent Clinical Isolates of Filamentous Fungi

  2003cited by this paper
• Genetic susceptibility to vaginal candidiasis.

  2003cited by this paper
• Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of Aspergillus spp. and Other Filamentous Fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000

  2002cited by this paper
• In Vitro Antifungal Susceptibilities of Trichosporon Species

  2002cited by this paper
• Efficacy of Ravuconazole in Treatment of Systemic Murine Histoplasmosis

  2002cited by this paper
• Ravuconazole Eisai/Bristol-Myers Squibb.

  2002cited by this paper
• Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis.

  2002cited by this paper
• In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp

  2002cited by this paper
• Efficacy of Ravuconazole in Treatment of Mucosal Candidosis in SCID Mice

  2001cited by this paper
• Investigational Antifungal Agents

  2001cited by this paper
• Novel triazole antifungal agents

  2000cited by this paper
• In Vitro Activity of the New Triazole BMS-207147 againstAspergillus Species in Comparison with Itraconazole and Amphotericin B

  2000cited by this paper
• Quality Control Limits for Broth Microdilution Susceptibility Tests of Ten Antifungal Agents

  2000cited by this paper
• In Vitro Activities of Ravuconazole (BMS-207147) against 541 Clinical Isolates of Cryptococcus neoformans

  2000cited by this paper
• Candidiasis : pathogenesis, diagnosis, and treatment

  1993cited by this paper
• Single dose oral fluconazole vs intravaginal terconazole in treatment of Candida vaginitis. Comparison and pilot study.

  1992cited by this paper
• Treatment of vaginal candidosis--a UK patient survey 1989.

  1990cited by this paper
• Quantification of vaginal Candida albicans infections in rodents.

  1986cited by this paper
• Inhibition of experimental ascending urinary tract infection by an epithelial cell-surface receptor analogue

  1982cited by this paper

• Physicochemical evaluation and pharmacodynamics of itraconazole-loaded liquid crystal precursor for vaginal delivery

  2021cites this paper
• Thermosensitive Hydrogels as a Controlled Release System for Alkannin to Improve Localized Treatment of Candida Vaginitis after External Beam Radiotherapy in Vitro and in Vivo.

  2019cites this paper
• Targeting CYP51 for drug design by the contributions of molecular modeling

  2017cites this paper
• The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model

  2016cites this paper
• Characterisation of biofilm associated with bacterial vaginosis

  2016cites this paper
• Prediction of antigenic sites on ALS1 and HWP1 protein sequences in vaginal isolated C. albicans of using bioinformatics analysis

  2015cites this paper
• Candida Albicans Infections

  2014cites this paper